Single Arm, Monocentric, Pilot Feasibility Study on an Interactive Virtual Reality Program in 20 Complex In-clinic Palliative Care Patients
- Sponsor
- University Hospital, Strasbourg, France
- Study ID
- NCT07545928
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Anxiety
- Depression Disorders
- Fatigue, Mental
- Palliative Care
- Psychological Distress
- Refractory Pain
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- ZenctuaryVR+ Interactive Virtual Reality — DEVICEThe ZenctuaryVR+ intervention is an interactive virtual reality (VR) program delivered via a Head-Mounted Display (HMD) equipped with physiological biosensors (EEG and skin conductance). Participants are immersed in a calming natural environment where they perform simple, low-cognitive-load interactions (grabbing/moving virtual objects) to promote autonomy and provide distraction from refractory symptoms. The intervention is administered once daily for a 10-minute session over 14 consecutive days. Each session is supervised by a trained hospital psychologist or mental-health staff member who monitors the patient's experience in real-time via a tablet. Safety is ensured through a daily bedside "go/no-go" clinical assessment and the use of the VRISE scale to monitor for cybersickness. This supportive care tool is used alongside standard palliative pharmacological treatments.
Study Details
Palliative care patients frequently face a "symptom cluster" of pain (up to 96%), fatigue (up to 90%), and anxiety (up to 79%), which severely degrades their quality of life in their final months.The study is built on the concept of passive exposure therapy (VREP), which engages multiple senses to distract the brain from pain signals. By creating an "immersive distraction" or a "flow state," VR can activate the brain's reward networks and reduce activity in areas associated with pain perception. Unlike most existing VR research in palliative care which uses "passive" VR (like watching a 360-degree video), this study uses interactive VR. Patients can perform simple actions-like grabbing or dropping virtual objects-within a calming natural environment, which may better support their sense of autonomy and dignity. Because this is a pilot study, the "Go/No-Go" decision for future larger trials depends on a strict composite of three factors: * Adherence: The patient must complete at least 11 out of 14 planned daily sessions. * Duration: Each session must average at least 7.5 minutes of usable VR exposure. * Tolerance: The patient must experience no device-related serious adverse events and maintain a high average tolerance score (VRISE score ≥ 25).
Key Dates
- First listed
- Apr 22, 2026
- Start date
- Sep 1, 2026
- Status verified
- Apr 2026
- Primary completion
- Mar 1, 2027
- Completion
- Mar 1, 2027
Study Design
- Enrollment
- 20 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: Interactive Virtual Reality (VR) InterventionParticipants receive a daily 10-minute session of the "ZenctuaryVR+" interactive virtual reality program for 14 consecutive days. Unlike passive VR, this intervention allows patients to interact with a calming natural environment via a Head-Mounted Display (HMD) and hand controllers to support autonomy and provide distraction from refractory symptoms. The intervention is supervised by trained clinical staff who perform a daily bedside "go/no-go" assessment. It is administered as a non-pharmacological supportive care tool alongside standard palliative treatments to evaluate the feasibility, safety, and impact of interactive VR on pain, anxiety, and overall quality of life.
Primary Outcome Measure
Feasibility Success : Adherence [ Time Frame: During the 14-day intervention period. ]
Central Contacts
- Laurent CALVEL, PU-PH+33(0)6.28.07.12.74
Related Studies
- Resiniferatoxin to Treat Severe Pain Associated With Advanced CancerPHASE1 · Recruiting · National Institute of Dental and Craniofacial Research (NIDCR) · Bethesda, Maryland
- Evaluation of the PACE/PACENET BHL Clinical ProgramRecruiting · University of Pennsylvania · Philadelphia, Pennsylvania
- Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone PainPHASE1/PHASE2 · Not Yet Recruiting · National Institute of Neurological Disorders and Stroke (NINDS) · Bethesda, Maryland
- Creatine for Depressed Male and Female Methamphetamine UsersPHASE3 · Recruiting · Montana State University · Missoula, Montana